UPDATE: Morgan Stanley Starts Sophia Genetics SA (SOPH) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall St muted ahead of Nvidia results, hot inflation fuels rate-hike bets
- Oil slips as investors focus on Hormuz talks
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Cowen Starts Sophia Genetics SA (SOPH) at Outperform
August 17, 2021 5:49 AM EDTCowen analyst Doug Schenkel initiates coverage on Sophia Genetics SA (NASDAQ: SOPH) with a Outperform rating.
The analyst comments "SOPH is an emerging leader in the decentralization of comprehensive genetic testing; the company also seeks to expand into adjacencies, such as... More
UPDATE: Credit Suisse Starts Sophia Genetics SA (SOPH) at Outperform
August 17, 2021 4:27 AM EDT(Updated - August 17, 2021 4:43 AM EDT)
Credit Suisse analyst Katie Tryhane initiates coverage on Sophia Genetics SA (NASDAQ: SOPH) with a Outperform rating and a price target of $22.00.
The analyst comments "SOPH is a healthcare technology company offering a decentralized software platform that leverages... More
JPMorgan Starts Sophia Genetics SA (SOPH) at Overweight
August 17, 2021 4:20 AM EDTJPMorgan analyst Tycho W. Peterson initiates coverage on Sophia Genetics SA (NASDAQ: SOPH) with a Overweight rating and a price target of $23.00.
For an analyst ratings summary and ratings history on Sophia Genetics SA... More
